NONOF Quote, Financials, Valuation and Earnings

Galecto has a net margin of 37.18% compared to Novo Nordisk AS's net margin of --. Novo Nordisk AS's return on equity of 84.88% beat Galecto's return on equity of --.

Novo Nordisk AS has a consensus price target of --, signalling upside risk potential of 21.56%. On the other hand Galecto has an analysts' consensus of $6.00 which suggests that it could grow by 81%. Given that Galecto has higher upside potential than Novo Nordisk AS, analysts believe Galecto is more attractive than Novo Nordisk AS.

Novo Nordisk AS has a beta of 0.661, which suggesting that the stock is 33.871% less volatile than S&P 500. In comparison Galecto has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Novo Nordisk AS has a quarterly dividend of $1.14 per share corresponding to a yield of 2.12%. Galecto offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk AS pays 43.71% of its earnings as a dividend. Galecto pays out -- of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novo Nordisk AS quarterly revenues are $11B, which are larger than Galecto quarterly revenues of --. Novo Nordisk AS's net income of $4.1B is higher than Galecto's net income of -$2.5M. Notably, Novo Nordisk AS's price-to-earnings ratio is 23.19x while Galecto's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk AS is 8.01x versus -- for Galecto. Usually stocks with elevated PS ratios are considered overvalued.

Genmab AS has a net margin of 37.18% compared to Novo Nordisk AS's net margin of 27.27%. Novo Nordisk AS's return on equity of 84.88% beat Genmab AS's return on equity of 22.23%.

Novo Nordisk AS has a consensus price target of --, signalling upside risk potential of 21.56%. On the other hand Genmab AS has an analysts' consensus of $29.69 which suggests that it could grow by 29.87%. Given that Genmab AS has higher upside potential than Novo Nordisk AS, analysts believe Genmab AS is more attractive than Novo Nordisk AS.

Novo Nordisk AS has a beta of 0.661, which suggesting that the stock is 33.871% less volatile than S&P 500. In comparison Genmab AS has a beta of 0.956, suggesting its less volatile than the S&P 500 by 4.415%.

Novo Nordisk AS has a quarterly dividend of $1.14 per share corresponding to a yield of 2.12%. Genmab AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk AS pays 43.71% of its earnings as a dividend. Genmab AS pays out -- of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novo Nordisk AS quarterly revenues are $11B, which are larger than Genmab AS quarterly revenues of $715M. Novo Nordisk AS's net income of $4.1B is higher than Genmab AS's net income of $195M. Notably, Novo Nordisk AS's price-to-earnings ratio is 23.19x while Genmab AS's PE ratio is 13.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk AS is 8.01x versus 4.79x for Genmab AS. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of 37.18% compared to Novo Nordisk AS's net margin of 21.68%. Novo Nordisk AS's return on equity of 84.88% beat Eli Lilly and's return on equity of 78.25%.

Novo Nordisk AS has a consensus price target of --, signalling upside risk potential of 21.56%. On the other hand Eli Lilly and has an analysts' consensus of $951.98 which suggests that it could grow by 17.88%. Given that Novo Nordisk AS has higher upside potential than Eli Lilly and, analysts believe Novo Nordisk AS is more attractive than Eli Lilly and.

Novo Nordisk AS has a beta of 0.661, which suggesting that the stock is 33.871% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.404, suggesting its less volatile than the S&P 500 by 59.63%.

Novo Nordisk AS has a quarterly dividend of $1.14 per share corresponding to a yield of 2.12%. Eli Lilly and offers a yield of 0.69% to investors and pays a quarterly dividend of $1.50 per share. Novo Nordisk AS pays 43.71% of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Novo Nordisk AS quarterly revenues are $11B, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Novo Nordisk AS's net income of $4.1B is higher than Eli Lilly and's net income of $2.8B. Notably, Novo Nordisk AS's price-to-earnings ratio is 23.19x while Eli Lilly and's PE ratio is 65.71x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk AS is 8.01x versus 14.89x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.